Last reviewed · How we verify
NCT06613919
Six-months Versus Nine-months ATT for Ocular TB
Phase 4 trial testing Anti-Tuberculosis Treatment in Tuberculosis (TB) in 58 participants. Completed in 30 June 2023.
31 December 2022
Quick facts
| Lead sponsor | L.V. Prasad Eye Institute |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 58 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 3 locations across India, Thailand, Burma |
Drugs / interventions tested
- Anti-Tuberculosis Treatment — full drug profile →
- Anti-Tuberculosis Treatment — full drug profile →
Conditions studied
- Tuberculosis (TB) — all drugs for Tuberculosis (TB) →
- Uveitis — all drugs for Uveitis →
- Retinal Vasculitis — all drugs for Retinal Vasculitis →
- Choroiditis — all drugs for Choroiditis →
Sponsor
L.V. Prasad Eye Institute
Who can join
18 and older, any sex, with Tuberculosis (TB) or Uveitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if 6-months anti-TB therapy is not worse than 9-months therapy for the treatment of tubercular posterior uveitis. The main questions it aims to answer are: Does six-month therapy work as well as the nine-month therapy? Do any of the specific phenotypes of TB posterior uveitis respond better to any specific duration of anti-TB therapy? Participants: Took the standard dose of six- or nine-month ATT for TB posterior uveitis Visit the clinic as advised for checkups and tests
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06613919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tuberculosis (TB)
Currently open trials in the same condition.
- NCT06963606 — Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese P · NA · recruiting
- NCT07178860 — Respiratory Health and Wellbeing Post Pulmonary Tuberculosis · recruiting
- NCT06909799 — A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease · NA · recruiting
- NCT06997367 — Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV16 · Phase 2 · active not recruiting
- NCT06916962 — Examining Psycho-Socioeconomic Linkages in TB Care: The UPLIFT Trial · NA · recruiting
Other L.V. Prasad Eye Institute trials
Trials by the same sponsor.
- NCT04843839 — CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops · Phase 2 · unknown
- NCT04618510 — SEED-LVPEI Myopia Study · NA · unknown
- NCT03548805 — Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma · NA · completed
- NCT03541551 — Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy · NA · completed
- NCT03230058 — Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06613919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by L.V. Prasad Eye Institute
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06613919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing